Neumora TherapeuticsNMRA
About: Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Employees: 103
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
117% more call options, than puts
Call options by funds: $282K | Put options by funds: $130K
0% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 30
9.51% less ownership
Funds ownership: 49.72% [Q4 2024] → 40.22% (-9.51%) [Q1 2025]
16% less funds holding
Funds holding: 133 [Q4 2024] → 112 (-21) [Q1 2025]
35% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 49
67% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 1 (-2) [Q1 2025]
92% less capital invested
Capital invested by funds: $852M [Q4 2024] → $65.1M (-$786M) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Needham Ami Fadia | 624%upside $5 | Buy Reiterated | 13 May 2025 |
B of A Securities Geoff Meacham | 45%upside $1 | Underperform Downgraded | 2 Apr 2025 |
Stifel Paul Matteis | 190%upside $2 | Hold Downgraded | 7 Mar 2025 |
HC Wainwright & Co. Douglas Tsao | 2,507%upside $18 | Buy Reiterated | 7 Mar 2025 |
RBC Capital Brian Abrahams | 479%upside $4 | Sector Perform Reiterated | 4 Mar 2025 |
Financial journalist opinion
Based on 4 articles about NMRA published over the past 30 days









